Archive · 21 Sep 2026
Lords Mark Shares Hit Upper Circuit Amid Healthcare Growth Plans
Lords Mark is a small company whose shares trade below ₹100.
Its shares rose by the maximum allowed 5% during Monday’s trading.
The company says it wants to grow in medical testing, dialysis and medical equipment.
It expects these healthcare businesses to generate about ₹825 crore in revenue by FY27.
The larger group reported revenue of ₹307.68 crore and profit after tax of ₹33.18 crore for the quarter ending June 2026.
Investors may like the company’s plans because medical tests and dialysis can bring repeat demand.
However, the share price has been very weak over longer periods.
It has gained recently but remains far below its earlier levels.
Lords Mark shares rose 5% to ₹93.45 on the National Stock Exchange on 21 September.
The stock opened at ₹89.58, compared with a previous close of ₹89.
Management projects approximately ₹825 crore in FY27 revenue from diagnostics, MedTech and dialysis.
The wider group reported ₹307.68 crore revenue and ₹33.18 crore profit after tax for the quarter ended June 2026.
Despite gaining more than 49% in three months, the stock has fallen 86.05% year to date and 83.85% over one year.
- Who
- Lords Mark Industries and its management; investors trading its shares.
- What
- Lords Mark shares reached the 5% upper circuit at ₹93.45 on the National Stock Exchange, amid reported optimism about its healthcare expansion plans.
- When
- 21 September, during Monday trading; the cited group results cover the quarter ended June 2026.
- Where
- On the National Stock Exchange in India, while broader market activity was reported on the Bombay Stock Exchange and National Stock Exchange.
- Why
- The rise occurred amid positive market sentiment, easing crude oil prices, renewed foreign fund inflows and gains across Asian markets.
Growth Case
Risk Case
Healthcare expansion
Growth Case
The company says in-vitro diagnostics, dialysis and specialised diagnostic technologies could provide complementary growth engines and recurring consumable demand.
Risk Case
The ₹825 crore FY27 figure is management guidance rather than booked revenue, and the article does not provide standalone MedTech results.
Share-price outlook
Growth Case
The stock has delivered more than 49% in three months, reflecting recent momentum amid positive market sentiment.
Risk Case
The stock has fallen 86.05% year to date, 83.85% over one year, 71.01% over two years and 66.63% over five years.
- Upper-circuit price
- ₹93.45 per share
- Opening price
- ₹89.58 per share
- Previous close
- ₹89 per share
- Projected FY27 healthcare revenue
- Approximately ₹825 crore from IVD, MedTech and dialysis
- Quarterly consolidated revenue
- ₹307.68 crore for the quarter ended June 2026
- Quarterly consolidated PAT
- ₹33.18 crore for the quarter ended June 2026
- Recent performance
- More than 49% return in three months; down 86.05% year to date